Research Paper Volume 14, Issue 8 pp 3597—3606
Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
Figure 4. The combination of trametinib and JQ1 via different cell death modes inhibits pancreatic cancer. (A) Cell lysates prepared from PSN-1 cells treated with trametinib alone, JQ1 alone, trametinib+JQ1, and trametinib+JQ1+HCQ over a time course were analyzed by immunoblotting for p62, LC3, or actin, as indicated. (B) Cell lysates prepared from CFPAC-1 cells treated with trametinib alone, JQ1 alone, trametinib+JQ1, and trametinib+JQ1+HCQ over a time course were analyzed by immunoblotting for p62, LC3, or actin, as indicated. (C) Model of the synergistic effects induced by the combination treatment of trametinib and JQ1 in KRAS mutant pancreatic cancer.